I fell in love with this place nearly 20 years ago because it reminded me of a premier venture capital firm. I draw this analogy because Damon Runyon has been associated with almost every breakthrough in cancer research despite the fact that we only grant around $18-20 million a year - tiny player, enormous impact."
Andrew S. Rachleff
* Indicates member serves on the Scientific Committee
William G. Kaelin, Jr., MD*
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute and
Harvard Medical School
Howard Hughes Medical Institute Investigator
Boston, Massachusetts
Lawrence W. Cohen
Founder, Partner and CEO
Seven Bridges Advisors, LLC
New York, New York
Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth & Zabel LLP
New York, New York
Receiving a Damon Runyon Fellowship had a tremendous impact on my scientific career. I also have been fortunate to mentor new Damon Runyon scientists in my lab who have gone on to have exemplary independent careers. Damon Runyon builds generations of scientific leaders and mentors.”
Carlos L. Arteaga, MD*
Director of the Harold C. Simmons Comprehensive Cancer Center
Associate Dean of Oncology Programs
Professor of Medicine
Annette Simmons Distinguished University Chair in Breast Cancer Research
University of Texas Southwestern Medical Center
Dallas, Texas
David M. Beirne
General Partner
X10 Capital
San Francisco, California
Melissa L. Cohn
Regional Vice President
William Raveis Mortgage LLC
Delray Beach, FL
Deborah J. Coleman*
Boston, Massachusetts
Robyn Coles
President
TRATE Properties LLC
Boston, Massachusetts
Gary E. Erlbaum
President
Greentree Properties
Ardmore, Pennsylvania
Buck French
General Partner
X10 Capital
San Francisco, California
Elaine V. Fuchs, PhD*
Head, Laboratory of Mammalian Cell Biology and Development
Rebecca C. Lancefield Professor
The Rockefeller University
Howard Hughes Medical Institute Investigator
New York, New York
Levi A. Garraway,
MD, PhD*
Executive Vice President
Chief Medical Officer and Head of Product Development
Genentech/Roche, Inc.
South San Francisco, California
Damon Runyon is one of the most successful and impactful organizations when it comes to support of the next generation of leaders in cancer research. Our ability to advance the understanding and treatment of cancer depends on the intellectual creativity and firepower of the people doing the research, so I wanted to be a part of ensuring that this organization can continue and grow its remarkable impact.”
Richard B. Gaynor, MD*
President and Chief of Research and Development
BioNTech US
Cambridge, Massachusetts
Erica Evans Gioffre
Management Committee Member
Hirtle, Callaghan & Company
West Conshohoken, PA
Todd R. Golub, MD*
Director and Founding Core Institute Member
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Professor of Pediatrics
Harvard Medical School
Cambridge, Massachusetts
David A. Gordon, PhD
Strategist
Bridgewater Associates
Westport, CT
Scott Greenstein
President and Chief Content Officer
SiriusXM
New York, New York
Richard Hoffman
Partner
Goodwin Proctor LLP
Boston, Massachusetts
Morana Jovan-Embiricos, PhD*
Managing Partner
F2 Capital Ventures LLP
London, United Kingdom
Steven A. Kandarian
Chairman, President and Chief Executive Officer (Retired)
MetLife, Inc
North Palm Beach, Florida
Gabrielle Layton, PhD
Palo Alto, California
Gerald M. Marshall
President & CEO, Netrality Data Centers
Chairman & CEO, Amerimar Enterprises, Inc.
Miami Beach, FL
Richard W. Meier
Director
The Bakewell Foundation
St. Louis, Missouri
Richard J. O’Reilly, MD*
Claire L. Tow Chair, Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York
Joseph Pearlberg, MD, PhD
Vice President of Scientific Affairs, Therapeutics
Deerfield Management Company
New York, New York
Lori J. Pierce, MD*
Professor, Radiation Oncology
University of Michigan
Rogel Cancer Center
Ann Arbor, MI
Adam R. Schwartz
Managing Partner and Global Head of Real Estate
TPG Angelo Gordon
New York, NY
Michael V. Seiden, MD, PhD*
Chief Executive Officer and Co-founder
Gladius Therapeutics
The Woodlands, Texas
Nancy Simonian, MD*
Chief Executive Officer (Retired)
Syros Pharmaceuticals, Inc.
Cambridge, Massachusetts
Amoolya Singh, PhD
Chief Technology Officer
Delfi Diagnostics
Palo Alto, CA and Baltimore, MD
Cynthia Sulzberger
Wellington, Florida
Judy C. Swanson
Hillsborough, California
Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California
James A. Wells, PhD*
Professor, Department of Pharmaceutical Chemistry
University of California, San Francisco
San Francisco, California
Yung S. Lie, PhD
President and Chief Executive Officer
Damon Runyon Cancer Research Foundation
New York, New York
© COPYRIGHT DAMON RUNYON. ALL RIGHTS RESERVED
